Literature DB >> 22495491

Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies.

A Hannemann1, M Bidlingmaier, N Friedrich, J Manolopoulou, A Spyroglou, H Völzke, F Beuschlein, J Seissler, R Rettig, S B Felix, R Biffar, A Döring, C Meisinger, A Peters, H E Wichmann, M Nauck, H Wallaschofski, M Reincke.   

Abstract

OBJECTIVE: The prevalence of primary aldosteronism in unselected hypertensive patients is currently unknown. We investigated the frequency of positive screening results for primary aldosteronism based on the aldosterone-to-renin ratio (ARR) in hypertensive subjects aged 30-79 years from two German epidemiological studies. We further examined the frequency of positive screening results in subjects with resistant hypertension or stage III hypertension and assessed possible disparities between untreated and treated hypertensive subjects.
METHODS: Data were obtained from the first follow-ups of the population-based study of health in Pomerania (SHIP; n=1392) and the cooperative health research in the region of Augsburg (KORA; n=1052). Study-specific reference ranges for plasma aldosterone concentration (PAC), plasma renin concentration (PRC) and the ARR were applied. Confirmation tests for primary aldosteronism were not performed in these epidemiological studies.Three definitions for a positive screening for primary aldosteronism were applied: A) increased ARR; B) increased ARR and decreased PRC; and C) increased ARR and increased PAC and decreased PRC.
RESULTS: The frequency of positive screening results was 7.0, 3.8 and 0.2% according to definitions A-C respectively. In the subgroups of subjects with resistant hypertension (11.9, 5.5 and 0.9%) or stage III hypertension (18.3, 14.0 and 1.1%), these frequencies were markedly higher than those in the general hypertensive population. There was no difference in the frequency of positive screening results between the treated and untreated hypertensive subjects.
CONCLUSIONS: A maximum of 7.0% of the hypertensive population in Germany shows a positive screening result for primary aldosteronism. Thus, primary aldosteronism may be less frequent than previously expected based on data from referred hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22495491     DOI: 10.1530/EJE-11-1013

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  26 in total

1.  Different Somatic Mutations in Multinodular Adrenals With Aldosterone-Producing Adenoma.

Authors:  Fabio Luiz Fernandes-Rosa; Isabelle Giscos-Douriez; Laurence Amar; Celso E Gomez-Sanchez; Tchao Meatchi; Sheerazed Boulkroun; Maria-Christina Zennaro
Journal:  Hypertension       Date:  2015-09-08       Impact factor: 10.190

Review 2.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

3.  Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension.

Authors:  Felix Beuschlein; Sheerazed Boulkroun; Andrea Osswald; Thomas Wieland; Hang N Nielsen; Urs D Lichtenauer; David Penton; Vivien R Schack; Laurence Amar; Evelyn Fischer; Anett Walther; Philipp Tauber; Thomas Schwarzmayr; Susanne Diener; Elisabeth Graf; Bruno Allolio; Benoit Samson-Couterie; Arndt Benecke; Marcus Quinkler; Francesco Fallo; Pierre-Francois Plouin; Franco Mantero; Thomas Meitinger; Paolo Mulatero; Xavier Jeunemaitre; Richard Warth; Bente Vilsen; Maria-Christina Zennaro; Tim M Strom; Martin Reincke
Journal:  Nat Genet       Date:  2013-02-17       Impact factor: 38.330

Review 4.  Adrenal Diagnostics: An Endocrinologist's Perspective focused on Hyperaldosteronism.

Authors:  Peter J Fuller
Journal:  Clin Biochem Rev       Date:  2013-11

Review 5.  Aldosterone as a mediator of severity in retinal vascular disease: Evidence and potential mechanisms.

Authors:  Michael J Allingham; Priyatham S Mettu; Scott W Cousins
Journal:  Exp Eye Res       Date:  2019-08-31       Impact factor: 3.467

6.  Adrenal venous sampling: the learning curve of a single interventionalist with 282 consecutive procedures.

Authors:  Hugo Jakobsson; Katerina Farmaki; Augustinas Sakinis; Olof Ehn; Gudmundur Johannsson; Oskar Ragnarsson
Journal:  Diagn Interv Radiol       Date:  2018 Mar-Apr       Impact factor: 2.630

7.  Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay.

Authors:  Ryo Morimoto; Yoshikiyo Ono; Yuta Tezuka; Masataka Kudo; Sachiko Yamamoto; Toshiaki Arai; Celso E Gomez-Sanchez; Hironobu Sasano; Sadayoshi Ito; Fumitoshi Satoh
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

Review 8.  Somatic mutations of the ATP1A1 gene and aldosterone-producing adenomas.

Authors:  Celso E Gomez-Sanchez; Maniselvan Kuppusamy; Elise P Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2014-12-10       Impact factor: 4.102

Review 9.  Aldosterone and the risk of hypertension.

Authors:  Vanessa Xanthakis; Ramachandran S Vasan
Journal:  Curr Hypertens Rep       Date:  2013-04       Impact factor: 5.369

10.  Screening for secondary endocrine hypertension in young patients.

Authors:  Raluca Trifanescu; Mara Carsote; Andra Caragheorgheopol; Dan Hortopan; Anda Dumitrascu; Mariana Dobrescu; Catalina Poiana
Journal:  Maedica (Buchar)       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.